edgepedia

Life and health

72,234 articles

Ido Golding

Ido Golding is a biological physicist and professor at the University of Illinois Urbana-Champaign known for measuring gene expression and viral infection inside individual bacterial cells.

Idoceras

Idoceras Burckhardt, 1906 is an extinct Upper Jurassic ammonite genus of Perisphinctidae (Idoceratinae), type species Ammonites balderus, erected at Mazapil, Mexico, and index genus for the Oxfordian–Kimmeridgian Planula and Balderus zones.

Idrabiotaparinux sodium

Idrabiotaparinux sodium (SSR126517E) is a biotinylated, once-weekly injectable indirect factor Xa inhibitor pentasaccharide derived from idraparinux, reversible with avidin; tested in EQUINOX, CASSIOPEA, and BOREALIS-AF but never marketed.

Idraparinux

Idraparinux (SANORG 34006, SR 34006) is a synthetic, antithrombin-dependent factor Xa inhibitor pentasaccharide, an analogue of fondaparinux, given as 2.5 mg weekly subcutaneous injections; phase III trials showed excess bleeding and development ceased.

Idursulfase

Idursulfase (Elaprase) is recombinant human iduronate-2-sulfatase enzyme replacement therapy for Hunter syndrome (MPS II), given weekly at 0.5 mg/kg IV; FDA-approved July 24, 2006, EU 2007; does not cross the blood-brain barrier.

Idursulfase beta

Idursulfase beta (Hunterase, GC1111) is a CHO-cell recombinant iduronate-2-sulfatase for weekly IV enzyme replacement therapy in Hunter syndrome (MPS II), approved in Korea in 2012, with higher FGly content and specific activity than idursulfase (Elaprase).

IE regimen (chemotherapy)

The IE regimen, also known as the Ifosfamide-Etoposide Rhabdomyosarcoma Regimen, pairs ifosfamide with etoposide for five days, used front-line and as salvage therapy for rhabdomyosarcoma, Ewing sarcoma, and osteosarcoma.

IEC 60601

IEC 60601, the IEC series on basic safety and essential performance of medical electrical equipment; general standard 60601-1 (edition 3.2, 2020), collateral standards such as 60601-1-2 EMC, and over 80 particular 60601-2-X device standards.

Iekuni Ichikawa

Iekuni Ichikawa is a Japanese-born nephrologist and pediatric physician-scientist who trained at UCSF and Harvard and spent 1985 to 2015 at Vanderbilt University, where his research helped establish CAKUT as a disease entity.

Ifebemtinib

Ifebemtinib (IN10018, BI 853520) is an oral, ATP-competitive FAK (PTK2) inhibitor developed by Boehringer Ingelheim and now InxMed, in Phase III for platinum-resistant ovarian cancer and combined with KRAS G12C inhibitors.

Iferanserin

Iferanserin (MPEC, MSA-100, VEN 309) is a peripheral 5-HT2A receptor antagonist developed as a 0.5% intra-anal ointment for internal hemorrhoids; its Phase 3 trial failed and development was discontinued in June 2012.

IFI16

IFI16 (IFNGIP1, PYHIN2), human PYHIN-family nuclear DNA sensor with PYD and two HIN domains; senses viral dsDNA, drives STING interferon signaling, ASC inflammasomes, and viral gene silencing; absent in mice.

IFIH1

IFIH1 (interferon induced with helicase C domain 1, HGNC:18873) encodes MDA5, a cytoplasmic RIG-I-like receptor sensing long viral dsRNA via MAVS to induce type I interferon; gain-of-function causes Aicardi-Goutieres and Singleton-Merten syndromes, loss-of-function causes severe viral infections.

Ifinatamab deruxtecan

Ifinatamab deruxtecan (I-DXd, DS-7300) is a B7-H3-directed antibody-drug conjugate with a DXd topoisomerase I inhibitor payload, DAR 4, developed by Daiichi Sankyo and Merck for SCLC, prostate, and esophageal cancers; FDA priority review 2026.

IFIT1

IFIT1, also known as P56 or ISG56, is a human antiviral protein induced by interferon that recognizes viral RNA lacking host-specific 5′ modifications and blocks its translation.

IFITM3

IFITM3 (interferon-induced transmembrane protein 3, 1-8U) is a 133 amino acid type II transmembrane restriction factor on chromosome 11 that blocks viral membrane fusion in endosomes, limiting influenza, dengue, Ebola, and SARS-CoV-2 entry.

IFNA2

IFNA2 (interferon alpha 2, Gene ID 3440) is a single-exon human gene at 9p21.3 encoding IFN-α2, the prototypic type I interferon; recombinant IFNα2a/2b (Roferon-A, Intron A) treat leukemia and viral hepatitis.

IFNAR1

IFNAR1 (interferon alpha/beta receptor 1, UniProt P17181) is the low-affinity subunit of the human type I interferon receptor with IFNAR2, signaling via TYK2/JAK1-STAT; targeted by anifrolumab for lupus.

IFNAR2

IFNAR2 (interferon alpha and beta receptor subunit 2, gene ID 3455, 21q22.11) encodes the primary ligand-binding chain of the human type I interferon receptor with IFNAR1, signaling via JAK1-STAT; mutations cause Immunodeficiency 45.

IFNB1

IFNB1 (interferon beta 1, IFN-beta, fibroblast interferon) is the single intronless human gene on chromosome 9p21.3 encoding type I interferon beta, which signals via IFNAR1/IFNAR2 Jak-STAT and whose recombinant products were the first MS disease-modifying therapies.

IFNfreeCOG trial

IFNfreeCOG (NCT02469012), a German trial of neurocognitive performance and emotional state in chronic hepatitis C patients on interferon-free sofosbuvir-based therapy, run by University of Wuerzburg at Burghausen with TAP, SF-36, HADS, and FIS-D measures.

IFNGR1

IFNGR1 (interferon gamma receptor 1), chromosome 6q23.3, encodes the ligand-binding chain of the IFN-γ receptor; mutations cause Mendelian susceptibility to mycobacterial disease, autosomal recessive or dominant.

IFNL3

IFNL3 (formerly IL28B) is a human gene on chromosome 19q13.2 encoding interferon-lambda 3, a type III interferon. Variants near it, notably rs12979860 and rs8099917, strongly predict hepatitis C clearance and interferon-based treatment response.

IFNL4

IFNL4 (interferon lambda 4 gene, chromosome 19q13.13) encodes IFN-λ4, a type III interferon produced only in carriers of the ΔG allele of rs368234815; discovered 2013, it impairs hepatitis C virus clearance, unlike the protective TT frameshift allele.

Ifosfamide

Ifosfamide is an intravenous chemotherapy drug of the oxazaphosphorine class, a structural isomer of cyclophosphamide introduced in 1967, used against sarcoma, lymphoma, testicular cancer, and lung and ovarian cancers.

Ifosfamide/doxorubicin regimen

The ifosfamide/doxorubicin (ID, or Dox-Ifos) regimen is a combination chemotherapy pairing ifosfamide with doxorubicin, given in 21-day cycles mainly to treat soft-tissue sarcomas, including rhabdomyosarcoma.

Ifupinostat hydrochloride for injection

Ifupinostat hydrochloride for injection (BEBT-908, CUDC-908) is an intravenous dual PI3Kα/HDAC inhibitor approved in China on 30 June 2025 for relapsed or refractory diffuse large B-cell lymphoma after two prior systemic therapies; the first dual HDAC/PI3K inhibitor approved anywhere.

Ig-like domain CHU_C associated

Ig_7 (PF19081), Ig-like domain CHU_C associated: a presumed immunoglobulin-like Pfam domain in Bacteroidetes, found as tandem repeats in T9SS surface proteins carrying the CHU_C C-terminal domain, such as CHU_3220 of Cytophaga hutchinsonii.

IgA nephropathy

IgA nephropathy (Berger's disease) is an autoimmune kidney disease with IgA deposits in glomeruli, first described in 1968; the most common primary glomerular disease worldwide, causing hematuria, proteinuria, and kidney failure in roughly 20-50% of patients.

IgA pemphigus

IgA pemphigus (immunoglobulin A pemphigus, intercellular IgA dermatosis) is a rare autoimmune blistering disease with IgA antibodies against desmocollins or desmogleins, causing annular vesicopustular eruptions treated with dapsone and steroids.